Focus: Parexel is a large Contract Research Organization (CRO) headquartered in Boston with 10,001–50,000 employees, providing clinical development, regulatory, and operations services across the pharmaceutical development lifecycle. As a major CRO, it executes trials and regulatory strategies for global pharma and biotech clients.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
Hot — 436 jobs added in 30d
Net +173 (436 new, 263 removed). Aggressive expansion phase.
Parexel is an excellent destination for clinical operations, regulatory affairs, and project management professionals seeking large-scale trial portfolio exposure and geographic expansion opportunities, but private status and limited visa sponsorship warrant due diligence on stability and relocation policies.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Parexel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Parexel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Parexel recognised among world's top disability inclusive businesses - Indian Pharma Post
Parexel recognised among world's top disability inclusive businesses Indian Pharma Post
Parexel launches Biotech Incubator for early-stage therapeutics - Express Pharma
Parexel launches Biotech Incubator for early-stage therapeutics Express Pharma
Parexel Launches Parexel Biotech Incubator - Contract Pharma
Parexel Launches Parexel Biotech Incubator Contract Pharma
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India - Indian Pharma Post
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India Indian Pharma Post
High-value clinical research marks gradual shift to India: Parexel - Business Standard
High-value clinical research marks gradual shift to India: Parexel Business Standard
Parexel buys Vitrana to boost patient safety toolkit - pharmaphorum
Parexel buys Vitrana to boost patient safety toolkit pharmaphorum
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies.
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo